Stimulant abuse (e.g. cocaine and methamphetamine) is a major public health problem in the United States. The abuse of CMS stimulants potentiates the impact and progression of HIV-1, hepatitis B and C, and drug resistant tuberculosis. A large body of evidence indicates that kappa opioid receptors may be involved in the modulation of some abuse related effects of CNS stimulants. Thus, kappa opioid receptors offer a pharmacological target to treat stimulant abuse and its attendant pathology, as well as, various types of pain. Kappa opioid receptors have also been implicated in the actions of Salvia divinorum, a hallucinogenic mint plant that is currently unscheduled and readily available to the public over the Internet. Due to the recent increase in the popularity of Salvia divinorum among both European and American teens, the DEA has recently placed it on the list of drugs to watch. It is predictable that its misuse will increase rapidly. In addition, few studies have been conducted on the pharmacological mode of action of Salvia divinorum or its active component, salvinorin A. The central hypothesis of this proposal is that structural modification of salvinorin A will lead to identification of novel kappa opioid receptor ligands with the potential to treat drug dependence and its relapse. The long-term goal of this research is to more fully understand the role of kappa opioid receptor function in treating drug dependence, as well as in hallucinogenic-like activity.
The specific aims of this proposal are (1) identify novel ligands for kappa opioid receptors based on the structure of the natural product salvinorin A and (2) identify the role of structural conformation on salvinorin A's affinity and activity. The innovative approach employed in this proposal utilizes medicinal chemistry, in vitro pharmacology and in vivo pharmacology to achieve our goals. This proposal represents a new template for the study of kappa opioid receptors ligands in drug dependence and analgesia.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA018151-05
Application #
7686816
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Hillery, Paul
Project Start
2005-09-30
Project End
2010-08-31
Budget Start
2009-09-01
Budget End
2010-08-31
Support Year
5
Fiscal Year
2009
Total Cost
$311,320
Indirect Cost
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Sherwood, Alexander M; Prisinzano, Thomas E (2018) Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens. Expert Rev Clin Pharmacol 11:1-3
Sherwood, Alexander M; Williamson, Samuel E; Johnson, Stephanie N et al. (2018) Scalable Regioselective and Stereoselective Synthesis of Functionalized (E)-4-Iodobut-3-en-1-ols: Gram-Scale Total Synthesis of Fungal Decanolides and Derivatives. J Org Chem 83:980-992
Zhou, Yan; Crowley, Rachel; Prisinzano, Thomas et al. (2018) Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice. Neurosci Lett 673:19-23
Kivell, Bronwyn M; Paton, Kelly F; Kumar, Nitin et al. (2018) Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents. Molecules 23:
Valenza, Marta; Butelman, Eduardo R; Kreek, Mary Jeanne (2017) ""Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats"". Psychopharmacology (Berl) 234:2219-2231
Paton, K F; Kumar, N; Crowley, R S et al. (2017) The analgesic and anti-inflammatory effects of Salvinorin A analogue ?-tetrahydropyran Salvinorin B in mice. Eur J Pain 21:1039-1050
Karad, Somnath Narayan; Pal, Mohan; Crowley, Rachel S et al. (2017) Synthesis and Opioid Activity of Tyr1 -?[(Z)CF=CH]-Gly2 and Tyr1 -?[(S)/(R)-CF3 CH-NH]-Gly2 Leu-enkephalin Fluorinated Peptidomimetics. ChemMedChem 12:571-576
Zhou, Yan; Crowley, Rachel Saylor; Ben, Konrad et al. (2017) Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone. Brain Res 1662:75-86
Sherwood, Alexander M; Williamson, Samuel E; Crowley, Rachel S et al. (2017) Modular Approach to pseudo-Neoclerodanes as Designer ?-Opioid Ligands. Org Lett 19:5414-5417
Sherwood, Alexander M; Crowley, Rachel Saylor; Paton, Kelly F et al. (2017) Addressing Structural Flexibility at the A-Ring on Salvinorin A: Discovery of a Potent Kappa-Opioid Agonist with Enhanced Metabolic Stability. J Med Chem 60:3866-3878

Showing the most recent 10 out of 68 publications